Results
Of 2,106 publications, 31 were included (N =
5,227 patients, 74% stentless
valves). Mean age was 65.4 years (74% male). Pooled early mortality was
5.5% (95% CI: 4.3-7.2%). During follow-up (mean 4.1 years, total
22.706 patient-years), late mortality was 4.8%/patient-year and
reoperation 0.9%/patient-year. Linearized-occurrence-rates for
thromboembolism, endocarditis, and hemorrhagic events:1.2; 0.9 and 0.5
%/patient-year; no significant difference between stented and stentless
prosthesis. Translating into a 60-year-old patient, an estimated life
expectancy of 14 years (general population: 22 years) and lifetime risks
of thromboembolism, endocarditis and reintervention of 21%, 13%, and
8%, respectively is expected.